Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(2)
•••
Comment by toinv261on Jan 26, 2017 9:43am
119 Views
Post# 25757475

RE:RE:RE:RE:RE:RE:RE:RE:RE:Kidney Foundations!! What the heck , where ya hiding??

RE:RE:RE:RE:RE:RE:RE:RE:RE:Kidney Foundations!! What the heck , where ya hiding??Thanks fuzzy and ledrog.

Makes sense. Funny thing is today the quotes seem to be in Canadian $. It must be the way that I am signing into SH. When I search RVX I no longer get SH bullboards showing up other than test.stockhouse..... and then I get a warning that I am not secure and get a post from BDAZ from Oct 15th 2015. Anyway, something has changed but I'll figure it out.

On a separate theme, I'd really like to hear and update on the zen3694 mCRPC pahse of the trial started in July of 2016. This is the phase of the trial with mCRPC and treated with zen3694 only and no enzalutimide. If they have been doing analysis on these patients and if they come up with valuable, positive results it could be another boast for epigenetics and Zenith and RVX in particular.

Cheers
Toinv
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities